Share this page:
Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data
There is significant international interest in heterologous prime-boost COVID-19 vaccination to mitigate against supply shocks or shortages that might otherwise reduce the speed of vaccine roll-out. Additionally, in light of changing recommendations regarding use of the ChAdOx1 nCoV-19 (ChAd) COVID-19 vaccine (Vaxzevria, AstraZeneca), several countries are now advising that individuals previously primed with this vaccine should now receive an alternative vaccine as their second dose, most commonly mRNA vaccines such as the BNT162b2 (BNT) COVID-19 vaccine (Comirnaty, Pfizer-BioNTech), administered in a heterologous prime-boost schedule.
Date Last Updated (Year-Month-Day)
Shaw, Robert H., Arabella Stuart, Melanie Greenland, Xinxue Liu, Jonathan S. Nguyen Van-Tam, and Matthew D. Snape. 2021. "Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data." The Lancet.
Free online on Lancet site.